340B Drug Pricing Program Eligibility Tied to Lower Biosimilar Use
- Participation in the 340B drug pricing program was associated with reduced biosimilar use and more biologic administrations, a study published in Health Affairs found. The 340B program allows eligible hospitals serving low-income populations to purchase discounted prescription drugs. Hospitals must have a disproportionate share hospital (DSH)...
